ABSTRACT. Dopamine is frequently used in neonatal
Circulating levels of G H and prolactin PRL have long been intensive care for its vasopressor, renal vasodilating, and known to be strikingly elevated in the newborn (1-3). Recently, cardiac inotropic properties. The effect of i.v. dopaminc deconvolution analysis of G H and PRL profiles revealed that infusion on nconatal pituitary hormone sccrction is cur-the nconatal hypersomatotropism is characterized by high-amrently unknown. \Ve observed strikingly low serum conccn-plitudc and high-frequency pulsatile secretion of G H without a [rations of growth hormone (GII) and prolactin (PRI,) prolonged G H half-life. whereas hyperprolactincmia appears to during a therapeutic, standardized, isovolumctric, partial be due to GH-independent, continuous PRL release (4) . exchange transfusion (blood sampling every 20 min for 6 Here, we provide evidence suggcstingthat dopaminc is a potent h) in two polycythemic neonates rcquiring intensive thcr-inhibitor of neonatal G H and PRL hypersecretion. apy, including continuous dopamine infusion. In addition, the secretion of GEI and PRL was studied in three nconatcs SUBJECTS A N D METIIODS with symptomatic polycythemia (gestational age 34-38 ~vk; birth weight 21 10-2530 g; postnatal age 10-30 h) during This report consists of two parts. one with G H and PRL a partial exchange transfusion, including an intervening profiles obtained in polycythemic newborns and one with paired dopamine infusion (8 pg/kg/min i.v. for 2 h). The GI1 and G H and PRL evaluations in nonpolycythemic neonates. The PRL profiles were evaluated by deconvolution analysis. serum G H and PRL profiles were obtained in a total of seven Initially, the three newborns exhibited high-amplitude, newborns. Thcse infants were admitted because of premature pulsatile GI1 secretion and continuously elevated PRI. birth. low birth weight, suboptimal cardiovascular condition. release. During the dopamine infusion, GI1 secretion was and/or respiratory distress. All infants were polycythemic, the virtually abolished and I'RL release was reduced by at median venous hematocrit being 0.7 (range 0.65-0.73). The least 50%. Dopaminc withdrawal was associated with a decision to perform a therapeutic partial exchange transfusion rebound release of GI1 and PRL. Finally, scrum GI1 and was made in each case by the attending neonatologist. Arterial PRL concentrations were studied in nine nonpolgcgthcmic blood samples were obtained every 20 min for 6 h during a newborns (gestational age 31-40 wk; birth weight 1680-standardized, isovolumctric, partial exchange transfusion. as prc-4000 g; postnatal age 2-28 d) a t the end of a prolonged viously described (5) . dopamine infusion (3-5 pg/kg/min i.v. for 2-27 d). Within The serum concentrations of G H were measured by RIA. 2 h after dopamine withdrawal. GI1 and I'RI, levels in-using a polyclonal antibody (6) : the intraassay coefficient of creased a median 3-fold and 10-fold respectively. Thcse variation was 5.89'0 at 35 pg/L. The serum concentrations of data concord to indicate that dopamine is a potent inhibitor PRL were measured by immunoradiomctric assay using the of GI1 and PRI. secretion in the human newborn. (Pediatr PRL-IRMA kit (Medgcnix. Flcurus, Belgium). having an intraasRes 34: 642-645, 1993) say coefficient of variation of 6.4% at 27 pg/L. All samples of each infant were assessed in the same assay run.
Abbreviations
The sequential G H and PRL concentrations of each infant were evaluated by multiple-parameter deconvolution analysis, a GI I, growth hormone technique examining the possibility of pulsatile hornione secre-PRL, prolactin tion, taking into account both the secretory episodes and the metabolic clearance of the investigated hormone (7). The profile part of this report consists of two sets of studies. First. the G H and PRL profiles from two newborns receiving Intravenous infusion of the catecholamine dopamine is rec-intensive care including positive pressure ventilation and dopaommendcd as the treatment of choice for cardiovascular support mine infusion (8 ~g/kg/min) were analyzed in comparison with of the newborn. As a result, dopamine administration has be-the profiles of two newborns not requiring intensive care. The come common practice in neonatal intensive care. However, latter infants were matched for gestational age. birth bvcight. dopamine is also a widely distributed neurotransmitter and, in postnatal age, hematocrit (~3 7 ; difference). and gender (male). addition, may act as a hormone on the hypothalamic-pituitary In second set of studies, G H and PRL profiles axis. ~t present, the effect of exogenous dopamine on the secre-obtained during a therapeutic partial exchange transfusion in tory dynamics of the neonatal anterior pituitary gland have not three newborns with symptomatic polycythcmia (gestational age been evaluated. accord with the clinical protocol that was used in our neonatal DOPAMINE EFFECT ON r UEONATAL Gf-I AND I'RL 643 intensive care unit at the time of these studies. During the piirtial exchange transfusion, all infants remained euglyccmic and had a normal percutaneous oxygen saturation. During the intervening dopamine infusion, the heart ratc was increased maximally by 20% compared with the heart ratc beforc and aftcr dopaminc administration. The second part of this report concerns nine nonpolycythemic newborns (gestational age 3 1-40 wk: birth weight 1680-4000 g: postnatal
RESULTS
The two examined newborns receiving intensivc care. including continuous dopamine infusion, were found to have dramatically decreased levels of G H and PRL compared with their matched controls (Fig. I) . Deconvolution analysis of these profiles indicated that the pulsatile sccretion of G H in the intensivc care patients was decreased in burst amplitude but not in burst frequency or burst duration (4) . The PRL secrction rates in the preterm and term infant receiving intensive care were calculated to be respectively one third and one tenth that in the controls.
In the three newborns receiving an intervening dopamine infusion, the latter was accompanied by a striking decrease in the serum concentrations of G H and PRL, whereas dopamine withdrawal was associated with a rapid normalization or transient overshoot of G H and PRL levels (Fig. 2) . Dcconvolution analysis of these three G H and PRL profiles revealed that the secretion of G H was virtually abolished during the dopamine infusion and was rcestablishcd after dopaminc withdrawal ( 3). The secrction of PRL was calculated to be decreased by 50% or more during the dopamine infusion and to be reinstated soon thereafter.
In the nine newborns studied at the end of a prolonged dopaminc infusion, serum G H concentrations rose ( p = 0.02) from a median 6 pg/L (range 5-19 pg/L) to 17 pg/L (range 9-53 pg/L) within 2 h after dopamine withdrawal, whereas PRL levels increased ( p = 0.002) from a median 5 pg/L (range <3-39 pg/L) to 54 pg/L (range 12-134 pg/L).
DISCUSSION
Strikingly low serum concentrations of G H and PRL were found in newborns receiving intensive care, including continuous dopamine infusion. Perinatal stress conditions are usually associated with excessively elevated G H and PRL levels (8, 9) . Thcreforc, the intensive treatment rather than the clinical condition itself was thought to induce the low G H and PRL lcvels found in thcse infants. The G H and PRL results from the three infants rcceiving an intervening dopamine infusion and from the nine infants at withdrawal of prolonged dopamine administration uniformly point toward dopamine as one of the causative factors within the intensive care setting. Together, thcse obscrvations provide direct and consistent evidence suggesting that dopaminc is a potent inhibitor of neonatal G H and PRL hypcrsccretion.
Our results support the concept that functional dopaminc receptors are present in the hypothalamo-pituitary axes governing G H and PRL sccretion in the human newborn. Although the concentration of dopamine in the human fetal hypothalamus exceeds that in the adult (lo), our data suggest that the dopamine receptors linked to the somatotropic or lactotropic axis are not maximally activated by endogenous dopamine secrction. It is plausible that the infused dopamine exerts its principal action on G H and PRL release directly at the pituitary level. Dopamine has bccn demonstrated to inhibit pituitary G H and PRL release in virro, through specific membrane-bound dopaminc receptors of the D2 subtype (I I). Moreover, human newborns receiving dopamine exhibit a blunted PRL response to exogenous thyrotropin releasing hormone (C. Vanhole, F. dc Zegher, H. Devlieger, ct ( I / . , unpublished observations).
It is noteworthy that the inhibitory responses of the newborn presenting with physiologic hypcrsecretion of G H and PRL parallel the inhibitory responses o f G H and PRL to dopaminergic agents in acromegalic adults with pathologic hypersonlatotropism and hyperprolactinemin (12) . Howcvcr, our findings rcgarding suppression of neonatal G H secrction by dopaminc contrast sharply with the stimulatory G H response to levodopa and/or dopamine in healthy children and adults (13, 14) . These discrepancies in neuroregulation may be related to multiple factors. including age-dependent differences in the number and efficacy of pituitary dopamine receptors and in the regulation of hypothalamic somatostatin secretion and action (1 1, 14, 15). The withdrawal of exogenous dopamine was found to evoke a brisk rebound increase in the secretion of G H and PRL. This finding suggests that the dissociation of dopamine from its receptor can function as a signal for G H and PRL release in the human newborn (1 6). This principle may have a clinical application. The endocrinologic exploration of G H deficiency in infancy is a technically difficult and frequently hazardous enterprise involving multiple blood sampling during, for example, insulin-induced hypoglycemia or a glucagon stimulation test (17). In view of our data, the potential of a "dopamine-withdrawal test" deserves further investigation as a novel alternative in the evaluation of infantile G H secretion.
The decreased secretion of G H and PRL induced by dopaminc in newborns may be of clinical significance. G H is an important regulator of intermediary metabolism and a potent growth stimulator at least from birth onward (8, 18) . Low plasma PRL concentrations in preterm infants have been associated with a poor outcome, possibly through effects of PRL on surfactant synthesis, whole body water regulation, and gastrointestinal maturation (19, 20) . In critically ill adults, the dopamine-induced hypoprolactinemia appears to be associated with a transient decrease of T-lymphocyte proliferative response (2 1).
In contrast to the brain, where multiple dopamine receptor subtypes exist, the anterior pituitary expresses exclusively dopamine receptors of the D2 subtype, which are present not only on somatotrophs and lactotrophs, but also on thyrotrophs and gonadotrophs (1 1, 22). Because activation of dopamine D2 receptors results predominantly in inhibitory responses, dopamine emerges as a potential suppressor of the secretion of multiple anterior pituitary hormones ( I I). In this study, we documented the effect of dopamine on neonatal G H and PRL secretion only. The extent of anterior hypopituitarism induced by dopamine in the newborn remains to be further delineated.
